DLH Holdings Corp Dossier - Source-backed chat

DLH Holdings Corp

DLHCNASDAQ

SectorIndustrials

IndustryResearch and Consulting Services

Beta (adjusted)1.31

Intrinsic Value $7.17median of 3 methodsbased on filings through 30 Jun 2026

Market Price $3.68Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 95% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+95%)

Data confidence Sign in to view data confidence

Market Cap $53.3M

Enterprise Value $179.4M

Shares Outstanding 14.5M diluted

Moat Rating None

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

DLH Holdings Corp. is currently navigating a significant transition year in fiscal 2026. The company's financial performance has been heavily pressured by the anticipated conversion of several legacy contracts (such as the Veterans Affairs CMOP pharmacy and logistic services) to small-business set-aside primes. This has resulted in a sharp year-over-year revenue decline and net losses. However, management has proactively right-sized its cost structure to align with its Technology Powered Solutions business base, successfully protecting its Adjusted EBITDA margins at around 9%. While the company carries a substantial debt load relative to its micro-cap size, it remains in compliance with all covenants and is focused on deploying second-half free cash flow toward deleveraging. A Hold recommendation is appropriate as the market waits for revenue stabilization and signs of organic growth from its digital modernization, cybersecurity, and AI pipeline.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$10.00

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.5015%

The bear case involves further delays in federal contract awards, continued labor cost inflation, or failure to win new programs to replace the transitioned legacy base. If revenue continues to deteriorate, the company's high leverage ($132.7 million in debt against a micro-cap equity base) could pressure liquidity, limit strategic investments, and potentially lead to covenant compliance issues or goodwill impairment.

Base CaseCentral scenario

$7.0060%

The base case assumes that contract transitions are completed in fiscal Q3 2026, establishing a new revenue baseline. Cost-scaling initiatives are expected to keep Adjusted EBITDA margins stable in the 9% range. Free cash flow generation in the second half of fiscal 2026 will be deployed to gradually reduce debt, while revenue begins to stabilize or grow modestly in fiscal 2027 as new task orders are slowly awarded.

Bull CaseUpside scenario

$10.0025%

The bull case relies on a faster-than-expected ramp-up of newly won contracts, high win rates on pending large bids, and rapid deleveraging. If DLH successfully leverages its proprietary Infinibyte Cloud platform and specialized health IT capabilities to capture high-margin federal modernization projects, profitability could recover quickly. Accelerated debt reduction would lower interest expenses, driving a significant re-rating of the stock toward historical multiples.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proactive cost-scaling initiatives that successfully protected Adjusted EBITDA margins at 9.0% during a steep revenue decline.
Strong competitive positioning in specialized federal health IT, clinical research, and cybersecurity, supported by proprietary platforms like Infinibyte Cloud.
High contract retention rates historically exceeding 90% and a solid relationship with key agencies like the NIH, which recently awarded a two-year sole-source extension.
Disciplined focus on free cash flow generation to pay down debt and improve the balance sheet.

Key Investment Risks

High concentration of revenue from federal government agencies, making the company vulnerable to budget delays, procurement cycles, and set-aside policy changes.
Significant revenue and earnings deterioration in fiscal 2026 due to the transition of legacy programs to small-business contractors.
Substantial debt load ($132.7 million as of March 31, 2026) relative to its market capitalization, resulting in elevated interest expenses.
Exposure to labor inflation and intense competition for specialized technical and clinical talent.

Thesis Invalidation Triggers

Failure to stabilize quarterly revenue above $55 million after the completion of legacy contract transitions in Q3 2026.
A deterioration in free cash flow that prevents the company from executing its planned debt prepayments.
Loss of additional major contracts or failure to secure key recompetes.
Breach of financial covenants under its secured credit agreement.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.